Résumé
A series of lipophilic ester derivatives (2a-g) of (S)-1-(pent-4′-enoyl)-4-(hydroxymethyl)-azetidin-2-one has been synthesised in three steps from (S)-4-(benzyloxycarbonyl)-azetidin-2-one and evaluated as novel, reversible, β-lactamic inhibitors of endocannabinoid-degrading enzymes (human fatty acid amide hydrolase (hFAAH) and monoacylglycerol lipase (hMAGL)). The compounds showed IC50 values in the micromolar range and selectivity for hFAAH versus hMAGL. The unexpected 1000-fold decrease in activity of 2a comparatively to the known regioisomeric structure 1a (i.e. lipophilic chains placed on N1 and C3 positions of the β-lactam core) could be explained on the basis of docking studies into a revisited model of hFAAH active site, considering one or two water molecules in interaction with the catalytic triad.
langue originale | Anglais |
---|---|
Pages (de - à) | 654-662 |
Nombre de pages | 9 |
journal | Journal of enzyme inhibition and medicinal chemistry |
Volume | 29 |
Numéro de publication | 5 |
Date de mise en ligne précoce | 9 oct. 2013 |
Les DOIs | |
Etat de la publication | Publié - 1 oct. 2014 |